• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

AST/ALT(De Ritis)比值对局限性肾细胞癌患者生存的影响及其与肿瘤组织病理学变量的关系。

The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma.

机构信息

Department of Urology, Okmeydani Training and Research Hospital, Istanbul, Turkey.

出版信息

Int Braz J Urol. 2018 Mar-Apr;44(2):288-295. doi: 10.1590/S1677-5538.IBJU.2017.0173.

DOI:10.1590/S1677-5538.IBJU.2017.0173
PMID:29211398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6050548/
Abstract

PURPOSE

To assess the relationship between De Ritis (aspartate aminotransaminase [AST]/Alanine aminotransaminase [ALT]) ratio and pathological variables and whether it is an independent prognostic factor.

MATERIALS AND METHODS

We analyzed 298 consecutive patients who underwent radical or partial nephrectomy for non-metastatic renal cell carcinoma (RCC) between 2006 and 2015. The association between De Ritis ratio and pathological variables including tumor size, presence of renal vein invasion, vena cava invasion, renal capsule infiltration, Gerota fascia invasion, renal sinus involvement, renal pelvic invasion, angiolymphatic invasion, adrenal gland involvement, lymph node involvement, tumor necrosis, and Fuhrman's grade was tested. Multivariable Cox analysis was performed to evaluate the impact of this ratio on overall survival and cancer-specific survival.

RESULTS

An increased preoperative De Ritis ratio was significantly associated with renal vein invasion, renal capsule infiltration and renal pelvis involvement (p<0.05) in non-metastatic RCC. On multivariate analysis we found that tumor size, Fuhrman grade and lymph node involvement were independent prognostic factors for cancerspecific survival. AST/ALT ratio had no influence on the risk of overall and cancerspecific survival.

CONCLUSION

An increased preoperative AST/ALT ratio had a significant association with renal vein invasion, renal capsule infiltration and renal pelvis involvement in patients with non-metastatic RCC. However, it does not appear to be an independent prognostic marker in non-metastatic RCC.

摘要

目的

评估 De Ritis(天冬氨酸氨基转移酶 [AST]/丙氨酸氨基转移酶 [ALT])比值与病理变量之间的关系,并探讨其是否为独立的预后因素。

材料与方法

我们分析了 2006 年至 2015 年间 298 例接受根治性或部分肾切除术的非转移性肾细胞癌(RCC)患者的资料。检验 De Ritis 比值与肿瘤大小、肾静脉侵犯、腔静脉侵犯、肾包膜浸润、Gerota 筋膜侵犯、肾窦累及、肾盂侵犯、血管淋巴管侵犯、肾上腺侵犯、淋巴结侵犯、肿瘤坏死和 Fuhrman 分级等病理变量之间的相关性。采用多变量 Cox 分析评估该比值对总生存和癌症特异性生存的影响。

结果

术前 De Ritis 比值升高与非转移性 RCC 的肾静脉侵犯、肾包膜浸润和肾盂侵犯显著相关(p<0.05)。多变量分析发现,肿瘤大小、Fuhrman 分级和淋巴结侵犯是癌症特异性生存的独立预后因素。AST/ALT 比值对总生存和癌症特异性生存的风险无影响。

结论

术前 AST/ALT 比值升高与非转移性 RCC 的肾静脉侵犯、肾包膜浸润和肾盂侵犯显著相关。然而,其似乎不是非转移性 RCC 的独立预后标志物。

相似文献

1
The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma.AST/ALT(De Ritis)比值对局限性肾细胞癌患者生存的影响及其与肿瘤组织病理学变量的关系。
Int Braz J Urol. 2018 Mar-Apr;44(2):288-295. doi: 10.1590/S1677-5538.IBJU.2017.0173.
2
De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.德瑞蒂斯比值(天冬氨酸转氨酶/丙氨酸转氨酶比值)作为透明细胞局限性肾细胞癌患者手术治疗后的重要预后因素:一项倾向评分匹配研究。
BJU Int. 2017 Feb;119(2):261-267. doi: 10.1111/bju.13545. Epub 2016 Jun 16.
3
The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients.德瑞蒂斯(天冬氨酸转氨酶/丙氨酸转氨酶)比值在预测局限性前列腺癌患者病理结果及预后中的意义。
Int Urol Nephrol. 2017 Aug;49(8):1391-1398. doi: 10.1007/s11255-017-1618-7. Epub 2017 May 26.
4
The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma.德瑞蒂斯(天门冬氨酸氨基转移酶/丙氨酸氨基转移酶)比值作为终末期肾病相关肾细胞癌患者的预后指标。
Clin Genitourin Cancer. 2020 Jun;18(3):236-240.e1. doi: 10.1016/j.clgc.2019.12.012. Epub 2019 Dec 17.
5
Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study.术前天门冬氨酸氨基转移酶/丙氨酸氨基转移酶比值评估在接受细胞减灭性肾切除术的转移性肾细胞癌患者中的独立预测生物标志物:一项倾向评分匹配研究。
Clin Genitourin Cancer. 2017 Oct;15(5):598-604. doi: 10.1016/j.clgc.2017.04.011. Epub 2017 Apr 20.
6
The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma.德瑞蒂斯(天冬氨酸转氨酶/丙氨酸转氨酶)比值作为上尿路尿路上皮癌患者术后肿瘤学预后的预测指标。
Int Urol Nephrol. 2017 Aug;49(8):1383-1390. doi: 10.1007/s11255-017-1613-z. Epub 2017 May 8.
7
Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.一线全身酪氨酸激酶抑制剂治疗转移性肾细胞癌患者中,治疗前天冬氨酸转氨酶/丙氨酸转氨酶比值的预后影响
Int J Urol. 2018 Jun;25(6):596-603. doi: 10.1111/iju.13574. Epub 2018 May 13.
8
The Preoperative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma.术前 AST/ALT(De Ritis)比值是无转移肾细胞癌患者预后不良的一个预测因素。
J Urol. 2015 Jul;194(1):30-5. doi: 10.1016/j.juro.2015.01.083. Epub 2015 Jan 23.
9
De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy.德瑞蒂斯(天冬氨酸转氨酶/丙氨酸转氨酶)比值作为上尿路尿路上皮癌患者肾输尿管切除术后无复发生存的重要预测指标。
Urol Oncol. 2016 Sep;34(9):417.e9-417.e15. doi: 10.1016/j.urolonc.2016.04.001. Epub 2016 May 11.
10
Clinical Significance of Pre-to-Postoperative Dynamics of Aspartate Transaminase/Alanine Transaminase Ratio in Predicting the Prognosis of Renal Cell Carcinoma after Surgical Treatment.术前至术后天门冬氨酸转氨酶/丙氨酸转氨酶比值动态变化对预测肾细胞癌手术治疗后预后的临床意义。
Dis Markers. 2020 Jul 4;2020:8887605. doi: 10.1155/2020/8887605. eCollection 2020.

引用本文的文献

1
Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy.使用治疗前炎症标志物的全身炎症评分预测肝细胞癌患者肝动脉灌注化疗后的预后
J Hepatocell Carcinoma. 2023 Dec 1;10:2133-2145. doi: 10.2147/JHC.S437329. eCollection 2023.
2
Association of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and De Ritis ratio with mortality in renal cell carcinoma: A multicenter analysis.中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值及德瑞蒂斯比值与肾细胞癌死亡率的相关性:一项多中心分析
Front Oncol. 2022 Nov 24;12:995991. doi: 10.3389/fonc.2022.995991. eCollection 2022.
3
An Increased Aspartate to Alanine Aminotransferase Ratio Is Associated With a Higher Risk of Cognitive Impairment.天冬氨酸与丙氨酸转氨酶比值升高与认知障碍风险增加相关。
Front Med (Lausanne). 2022 Apr 7;9:780174. doi: 10.3389/fmed.2022.780174. eCollection 2022.
4
Potential Clinical Value of Pretreatment De Ritis Ratio as a Prognostic Biomarker for Renal Cell Carcinoma.治疗前德瑞蒂斯比值作为肾细胞癌预后生物标志物的潜在临床价值
Front Oncol. 2021 Dec 21;11:780906. doi: 10.3389/fonc.2021.780906. eCollection 2021.
5
Aspartate aminotransferase/alanine aminotransferase ratio and subsequent cancer development.天门冬氨酸氨基转移酶/丙氨酸氨基转移酶比值与后续癌症发展。
Cancer Med. 2022 Feb;11(3):798-814. doi: 10.1002/cam4.4473. Epub 2021 Dec 1.
6
Elevated De Ritis Ratio as a Predictor for Acute Kidney Injury after Radical Retropubic Prostatectomy.De Ritis比值升高作为耻骨后根治性前列腺切除术后急性肾损伤的预测指标
J Pers Med. 2021 Aug 25;11(9):836. doi: 10.3390/jpm11090836.
7
The Association of Aspartate Aminotransferase/Alanine Aminotransferase Ratio with Diabetic Nephropathy in Patients with Type 2 Diabetes.2型糖尿病患者中天冬氨酸转氨酶/丙氨酸转氨酶比值与糖尿病肾病的关系
Diabetes Metab Syndr Obes. 2021 Sep 7;14:3831-3837. doi: 10.2147/DMSO.S330741. eCollection 2021.
8
Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors.德雷蒂斯比值在酪氨酸激酶抑制剂治疗转移性肾细胞癌中的预测价值。
World J Urol. 2021 Aug;39(8):2977-2985. doi: 10.1007/s00345-021-03628-2. Epub 2021 Mar 1.
9
Prognostic Role of Pretreatment De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase Ratio) in Urological Cancers: A Systematic Review and Meta-Analysis.治疗前德瑞蒂斯比值(天冬氨酸转氨酶/丙氨酸转氨酶比值)在泌尿系统癌症中的预后作用:一项系统评价和荟萃分析
Front Oncol. 2020 Sep 4;10:1650. doi: 10.3389/fonc.2020.01650. eCollection 2020.
10
AST/ALT ratio as a predictor of mortality and exacerbations of PM/DM-ILD in 1 year-a retrospective cohort study with 522 cases.AST/ALT 比值作为预测 PM/DM-ILD 1 年内死亡率和加重的指标:一项回顾性队列研究,共纳入 522 例病例。
Arthritis Res Ther. 2020 Sep 20;22(1):202. doi: 10.1186/s13075-020-02286-w.

本文引用的文献

1
Transaminase Activity Predicts Survival in Patients with Head and Neck Cancer.转氨酶活性可预测头颈癌患者的生存率。
PLoS One. 2016 Oct 12;11(10):e0164057. doi: 10.1371/journal.pone.0164057. eCollection 2016.
2
De Ritis Ratio (AST/ALT) as a Significant Prognostic Factor in Patients With Upper Tract Urothelial Cancer Treated With Surgery.德瑞蒂斯比值(谷草转氨酶/谷丙转氨酶)作为手术治疗上尿路尿路上皮癌患者的重要预后因素。
Clin Genitourin Cancer. 2017 Jun;15(3):e379-e385. doi: 10.1016/j.clgc.2016.08.023. Epub 2016 Sep 7.
3
De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.德瑞蒂斯比值(天冬氨酸转氨酶/丙氨酸转氨酶比值)作为透明细胞局限性肾细胞癌患者手术治疗后的重要预后因素:一项倾向评分匹配研究。
BJU Int. 2017 Feb;119(2):261-267. doi: 10.1111/bju.13545. Epub 2016 Jun 16.
4
Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma.肾静脉侵犯程度影响肾细胞癌患者的预后。
BJU Int. 2016 Jul;118(1):112-7. doi: 10.1111/bju.13349. Epub 2015 Nov 14.
5
Preoperative serum liver enzyme markers for predicting early recurrence after curative resection of hepatocellular carcinoma.用于预测肝细胞癌根治性切除术后早期复发的术前血清肝酶标志物。
Hepatobiliary Pancreat Dis Int. 2015 Apr;14(2):178-85. doi: 10.1016/s1499-3872(15)60353-8.
6
The Preoperative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma.术前 AST/ALT(De Ritis)比值是无转移肾细胞癌患者预后不良的一个预测因素。
J Urol. 2015 Jul;194(1):30-5. doi: 10.1016/j.juro.2015.01.083. Epub 2015 Jan 23.
7
Stage T3a renal cell carcinoma: staging accuracy of CT for sinus fat, perinephric fat or renal vein invasion.T3a期肾细胞癌:CT对窦脂肪、肾周脂肪或肾静脉侵犯的分期准确性
Br J Radiol. 2015 Jan;88(1045):20140504. doi: 10.1259/bjr.20140504.
8
Prognostic factors of distal cholangiocarcinoma after curative surgery: a series of 84 cases.根治性手术后远端胆管癌的预后因素:84例病例系列研究
Hepatogastroenterology. 2013 Nov-Dec;60(128):1892-5.
9
The de ritis ratio: the test of time.德瑞蒂斯比值:时间的考验。
Clin Biochem Rev. 2013 Nov;34(3):117-30.
10
Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.预测慢性乙型肝炎患者肝相关血清标志物发生肝细胞癌的风险。
PLoS One. 2013 Apr 17;8(4):e61448. doi: 10.1371/journal.pone.0061448. Print 2013.